Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
O6-alkylguanine-DNA alkyltransferase (AGT), also known as O6-methylguanine-DNA methyltransferase (MGMT), is a DNA repair protein that removes alkyl groups from the O6 position of guanine in DNA. This direct reversal mechanism protects cells from the mutagenic, cytotoxic, and carcinogenic effects of alkylating agents. The enzyme acts through a "suicide" mechanism, where it is irreversibly inactivated after accepting an alkyl group. High levels of AGT can confer resistance to chemotherapy drugs, making it a target for therapeutic intervention.
Direct reversal of DNA alkylation damage; "suicide" mechanism involving alkyl group transfer to a cysteine residue and subsequent enzyme inactivation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O6-Alkylguanine-DNA Alkyltransferase (AGT).